- Institutions (554)
- Austrian Institute for Health Technology Assessment (AIHTA) (293)
AIHTA, HTA Austria (2024): Annual Report 2023.
AIHTA, HTA Austria (2023): Annual Report 2022.
AIHTA, HTA Austria (2022): Annual Report 2021.
AIHTA, HTA Austria (2021): Annual Report 2020.
Auinger, D. (2022): Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for secondary peritoneal carcinomatosis: 1st Update. Decision Support Document 74/ Update 2022.
Auinger, D. and Sehic, O. (2023): Update PET/PET-CT evidence for need based planning in the area of oncology. AIHTA Policy Brief 003/ 3. Update.
Buzath, K. and Zechmeister-Koss, I. (2023): Economic Dimensions of Community Nursing: A Systematic Literature Review. HTA-Projektbericht 153.
Böhler, C.E.H. and Wolf, S. (2020): Lung Cancer Screening in Risk Groups: A Review-Update of the Economic Evidence (Part II). HTA-Projektbericht 132b.
Erdos, J. (2022): Percutaneous transvascular implantation of a coronary sinus reducing stent. 1. Update 2022. Decision Support Document 121/ Update 2022.
Erdos, J. and Formoso, G. and Djuric, O. and Bonvicini, L. and Pezzarossi, A. and Ballini, L. and Jeroncic, A. (2021): Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia – German Summary of the EUnetHTA OCTA27 Assessment. Decision Support Document 129.
Erdos, J. and Riegelnegg, M. and Sawalha, R. (2024): Electroconvulsive therapy in treatment-resistant depression and treatment-resistant schizophrenia. Decision Support Document 140.
Erdos, J. and Schmidt, L. and Reinsperger, I. (2024): Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer. HTA-Projektbericht 107/ 1. Update.
Erdos, J. and Sehic, O. and Wild, C. (2021): ≥ 12 Month Follow-Up of Patients with Spinal Muscular Atrophy (SMA) treated with Spinraza®, Zolgensma® or Combination Therapies. AIHTA Policy Brief 001/ 1. Update.
Ettinger, S. and Jeindl, R. (2023): Cipaglucosidase alfa (Pombiliti®) in combination with Miglustat for the treatment of adults with late-onset Pompe disease (acid α‑glucosidase [GAA] deficiency). Fact Sheet Nr. 124.
Ettinger, S. and Jeindl, R. and Erdös, J. (2023): Biomarkers in Alzheimer's Disease. Rapid Review Nr.: 004.
Ettinger, S. and Wild, C. (2023): CORE-MD Roadmap for Education & Training: Perceived training needs of regulators, notified bodies and clinicians for successful implementation of the EU MDR. AIHTA Policy Brief 000.
Forel, D. and Vandepeer, M. and Ma, N. and Goetz, G. (2023): Percutaneous aspiration thrombectomy for pulmonary embolism. Decision Support Document 135.
Frühwirth, I. and Wolf, S. (2022): Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess individual breast cancer risk, their utility and applicability in a breast cancer screening programme. HTA-Projektbericht 145.
Gassner, L. (2021): Implantation of Bulking Agents for Faecal Incontinence. Update 2021. Decision Support Document 87/1.
Gassner, L. and Al Froukh, R.F. and Goetz, G. (2023): Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor. Decision Support Document 136.
Gassner, L. and Hofer, V. (2022): Osteopathy: effectiveness and safety for musculoskeletal pain and overview of training and quality requirements. HTA-Projektbericht 144.
Gassner, L. and Mayer-Ferbas, J. (2020): Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia, Depression, Insomnia and Schizophrenia. HTA-Projektbericht 133.
Gassner, L. and Reinsperger, I. (2021): National strategies and programmes for preventing and managing non-communicable diseases in selected countries. HTA-Projektbericht 139.
Geiger-Gritsch, S. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: CAR-T Cell Therapy. AIHTA Policy Brief 006a.
Geiger-Gritsch, S. and Absenger, G. and Endel, F. and Flicker, M. and Hermann, A. and Kocher, F. and Olschewski, H. and Pall, G. and Wurm, M. and Zechmeister, M. (2021): Health Services Research in Oncology: Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Therapy in Real-World Practice. A Pilot Project in Cooperation with Tirol Kliniken GmbH & KAGes. HTA-Projektbericht 126.
Giess, D. and Erdos, J. and Wild, C. (2023): SMA-Therapies: Mid- to longer-term follow-up of spinal muscular atrophy (SMA) patients treated for ≥24 months with nusinersen or onasemnogene abeparvovec as monotherapies or in combination, and patients treated for ≥12 months with risdiplam as monotherapy or in combination. AIHTA Policy Brief 001/ 2. Update.
Glanz, K.A. (2021): Nivolumab in malignant melanoma: contrasting the evidence from pivotal trials with Real World Evidence (RWE). HTA-Projektbericht 140.
Goetz, G. (2021): Stool DNA testing for colorectal cancer (CRC) screening. AIHTA Policy Brief 011.
Goetz, G. and Giess, D. and Kern, J. (2024): Renal denervation (RDN) in patients with treatment resistant hypertension. Decision Support Document 45/ 2. Update 2024.
Goetz, G. and Hofer, V. and Jeindl, R. and Walter, M. (2022): Telemonitoring in Austrian diabetes care: A systematic analysis of evaluation methodologies. HTA-Projektbericht 143.
Goetz, G. and Walter, M. and Wohlhöfner, K. and Wittenberg, H. and Saal, S. and Stephan, K.M. and Dohle, C. (2021): Robotics and functional electrical stimulation for stroke rehabilitation. HTA-Projektbericht 128.
Goetz, G. and Wernly, B. (2022): Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest. Update 2022. Decision Support Document 103/ 2. Update 2022.
Gregor-Patera, N. (2023): Sponsoring of patient initiatives in Austria. 5th Update of the Systematic Analyses 2014 to 2019. AIHTA Policy Brief 007/ 5. Update.
Grössmann, N. (2021): Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer. Update May 2021. Oncology Fact Sheet Nr. 36.
Grössmann, N. (2021): Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. Update May 2021. Oncology Fact Sheet Nr. 40.
Grössmann, N. (2021): Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis. Update April 2021. Oncology Fact Sheet Nr. 33.
Grössmann, N. (2021): Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI-H or dMMR colorectal cancer. Update April 2021. Oncology Fact Sheet Nr. 34.
Grössmann, N. (2021): Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer. Update April 2021. Oncology Fact Sheet Nr. 37.
Grössmann, N. (2021): Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer. Update March 2021. Oncology Fact Sheet Nr. 32.
Grössmann, N. (2021): Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL). Update August 2021. Oncology Fact Sheet Nr. 44.
Grössmann, N. (2021): Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). Update August 2021. Oncology Fact Sheet Nr. 45.
Grössmann, N. (2021): Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). Update August 2021. Oncology Fact Sheet Nr. 46.
Grössmann, N. (2021): Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. Update February 2021. Oncology Fact Sheet Nr. 12.
Grössmann, N. (2021): Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC. Update February 2021. Oncology Fact Sheet Nr. 13.
Grössmann, N. (2021): Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL). Update February 2021. Oncology Fact Sheet Nr. 15.
Grössmann, N. (2021): Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Update February 2021. Oncology Fact Sheet Nr. 18.
Grössmann, N. (2021): Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Update February 2021. Oncology Fact Sheet Nr. 19.
Grössmann, N. (2021): Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC). Update February 2021. Oncology Fact Sheet Nr. 20.
Grössmann, N. (2021): Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC). Update February 2021. Oncology Fact Sheet Nr. 21.
Grössmann, N. (2021): Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer. Update February 2021. Oncology Fact Sheet Nr. 22.
Grössmann, N. (2021): Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC). Update February 2021. Oncology Fact Sheet Nr. 23.
Grössmann, N. (2021): Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer. Update February 2021. Oncology Fact Sheet Nr. 24.
Grössmann, N. (2021): Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL). Update February 2021. Oncology Fact Sheet Nr. 25.
Grössmann, N. (2021): Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC). Update February 2021. Oncology Fact Sheet Nr. 26.
Grössmann, N. (2021): Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM). Update February 2021. Oncology Fact Sheet Nr. 29.
Grössmann, N. (2021): A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer. Update February 2021. Oncology Fact Sheet Nr. 30.
Grössmann, N. (2021): Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Update August 2021. Oncology Fact Sheet Nr. 42.
Grössmann, N. (2021): Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM). Update August 2021. Oncology Fact Sheet Nr. 43.
Grössmann, N. (2021): Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen. Update February 2021. Oncology Fact Sheet Nr. 8.
Grössmann, N. (2020): Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma. Update February 2021. Oncology Fact Sheet Nr. 31.
Grössmann, N. (2020): Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL). Update February 2021. Oncology Fact Sheet Nr. 27.
Grössmann, N. (2020): Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions. Update July 2020. Oncology Fact Sheet Nr. 1.
Grössmann, N. (2020): Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML). Update July 2020. Oncology Fact Sheet Nr. 10.
Grössmann, N. (2020): Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer. Update July 2020. Oncology Fact Sheet Nr. 11.
Grössmann, N. (2020): Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC). Update July 2020. Oncology Fact Sheet Nr. 2.
Grössmann, N. (2020): Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC). Update July 2020. Oncology Fact Sheet Nr. 4.
Grössmann, N. (2020): Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL). Update July 2020. Oncology Fact Sheet Nr. 5.
Grössmann, N. (2020): Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM). Update July 2020. Oncology Fact Sheet Nr. 6.
Grössmann, N. (2020): Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Update July 2020. Oncology Fact Sheet Nr. 7.
Grössmann, N. (2020): Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma. Update July 2020. Oncology Fact Sheet Nr. 9.
Grössmann, N. (2020): Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL). Oncology Fact Sheet Nr. 14.
Grössmann, N. and Wild, C. (2020): Update PET/PET-CT evidence for need based planning in the area of oncology. AIHTA Policy Brief 003.
Grössmann, N. and Wolf, S. and Wild, C. (2021): Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD). Decision Support Document 127.
Grössmann-Waniek, N. and Strohmaier, C. and Riegelnegg, M. (2024): Oncological Breast Cancer Care in Selected European Countries – Cross-sectoral cancer care models. HTA-Projektbericht 162.
Hofer, V. and Goetz, G. (2023): Allogeneic mesenchymal stem cells for Crohn's Disease-associated complex perianal fistulas. 1st Update 2023. Decision Support Document 111/ Update 2023.
Hofer, V. and Wild, C. (2022): Upper airway stimulation for moderate-to-severe sleep apnoea. Update 2022. Decision Support Document 100/ Update 2022.
Huic, M. and Erdos, J. and Wild, C. (2024): Point of Care Tests (POCT): D-Dimer and Troponin. HTA-Projektbericht 124/ 1. Update.
Huic, M. and Goetz, G. (2023): Image-guided spinal injections in the treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques. HTA-Projektbericht 156.
Huic, M. and Reinsperger, I. (2023): Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patients/social, ethical and legal elements. HTA-Projektbericht 152.
Huić, M. (2021): Bamlanivimab monotherapy and as combination therapy (with Etesevimab) for Covid-19. AIHTA Policy Brief 009.
Huić, M. and Swiss Network for HTA, (SNHTA) (2021): Combination therapy Casirivimab plus Imdevimab (REGN-COV2) for the treatment of Covid-19. AIHTA Policy Brief 008.
Jeindl, R. and Ettinger, S. (2023): Radiofrequency denervation for chronic lumbar or cervical spine pain. Rapid Review Nr.: 003.
Jeindl, R. and Ettinger, S. (2023): iv Immunoglobulins (IgVena) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss. Rapid Review Nr.: 001.
Jeindl, R. and Ettinger, S. (2023): Extracorporeal shock wave therapy for orthopaedic indications. Rapid Review Nr.: 002.
Jeindl, R. and Goetz, G. (2021): Process and evaluation of digital health applications in the context of "symptom-checkers". HTA-Projektbericht 141.
Jeindl, R. and Goetz, G. (2021): Percutaneous left ventricular assist devices: micro-axial flow pumps. Decision Support Document 124.
Jeindl, R. and Hofer, V. (2022): Child and adolescent mental health care models. HTA-Projektbericht 149.
Jeindl, R. and Mayer-Ferbas, J. (2024): Massive parallel sequencing – technologies for high-throughput analysis of genetic-genomic data sets. Rapid Review Nr.: 015.
Jeindl, R. and Mayer-Ferbas, J. (2024): CAR-based immunotherapy with a focus on CAR-NK cells. Rapid Review Nr.: 013.
Jeindl, R. and Riegelnegg, M. (2023): Robot-assisted rehabilitation for incomplete spinal cord injury. Rapid Review Nr.: 005.
Jeindl, R. and Wernly, B. (2022): His-bundle-pacing for patients requiring a permanent pacemaker or cardiac resynchronisation. Decision Support Document 132.
Jeindl, R. and Wild, C. (2020): Framework for reimbursement decisions of digital health technologies (mHealth) and its (retrospective) application on selected examples. HTA-Projektbericht 134.
Jeindl, R. and Wolf, S. (2024): Calcitonin gene-related peptide antagonists for the prevention of migraine - summary of the BAG /RACS HTA report 2023. Rapid Review Nr.: 011.
Johansson, T. and Freundlinger, N. and Strohmaier, C. (2023): Bleomycin Electrosclerotherapy for Vascular Anomalies: Systematic Review. Decision Support Document 137.
Kern, J. and Reinsperger, I. and Hofer, V. (2024): Mental health screening of adults in primary care. HTA-Projektbericht 159.
Kheder, M. and Vandepeer, M. and Forel, D. and Tivey, D. (2021): Triphasic biomaterial for augmentation of the osteoporotic femoral neck. Decision Support Document 126.
Mayer-Ferbas, J. and Jeindl, R. (2024): Skin cancer prevention: Guideline recommendations for primary and secondary prevention. Rapid Review Nr.: 014.
Mayer-Ferbas, J. and Jeindl, R. (2024): Liposuction for the removal of subcutaneous (large) lipomas. Rapid Review Nr.: 009.
Mayer-Ferbas, J. and Riegelnegg, M. and Jeindl, R. (2023): Myopia control spectacle lenses for children and adolescents. Rapid Review Nr.: 006.
Mittermayr, T. (2024): Appraisal Board (Test). DSD: Bewertungsboard I.
Nicolopoulos, K. and Riegelnegg, M. and Hollyoak, R. and Vreugdenburg, T. (2024): Thermoablation for benign thyroid nodules. Decision Support Document 141.
Panhuber, A. and Titieni-Schuhmann, A. and Goetz, G. and Wild, C. (2022): CAR-T cell therapy: Contrasting the evidence from pivotal trials with the real world evidence (RWE). HTA-Projektbericht 146.
Reinsperger, I. (2022): Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries. AIHTA Policy Brief 012.
Reinsperger, I. (2021): Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence. AIHTA Policy Brief 005.
Reinsperger, I. and Paul, J. (2022): Perinatal and infant mental health care models and pathways. HTA-Projektbericht 148.
Riegelnegg, M. and Gassner, L. and Grössmann-Waniek, N. (2023): Robot-assisted surgery in thoracic and visceral indications – Update 2023. HTA-Projektbericht 108/ Update 2023.
Riegelnegg, M. and Giess, D. and Goetz, G. (2024): Artificial Intelligence in health care with a focus on hospitals: Methodological considerations for Health Technology Assessment. A Scoping Review. HTA-Projektbericht 164.
Riegelnegg, M. and Jeindl, R. (2023): Autologous fat grafting in osteoarthritis. Rapid Review Nr.: 007.
Rochet, E. and Stringer, D. and Gassner, L. and Vandepeer, M. and Forel, D. and Bachlani, A. and Duncan, J. (2022): Hepatic and portal vein embolisation prior to major hepatectomy. Decision Support Document 130.
Rothschedl, E. and Grössmann, N. (2024): Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC). Fact Sheet Nr. 184.
Rothschedl, E. and Grössmann, N. (2024): Toripalimab (Loqtorzi®) with cisplatin and paclitaxel for the first-line treatment of unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC). Fact Sheet Nr. 185.
Rothschedl, E. and Grössmann, N. (2024): Zolbetuximab (Vyloy®) with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2‑negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Fact Sheet Nr. 186.
Rothschedl, E. and Grössmann, N. (2024): Encorafenib (Braftovi®) in combination with binimetinib (Mektovi®) for the treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 187.
Rothschedl, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) with enfortumab vedotin (Padcev®) for the first-line treatment of unresectable or metastatic urothelial carcinoma. Fact Sheet Nr. 188.
Rothschedl, E. and Grössmann, N. (2024): Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 189.
Rothschedl, E. and Grössmann, N. (2024): Erdafitinib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC). Fact Sheet Nr. 180.
Rothschedl, E. and Grössmann, N. (2024): Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuse large B‑cell lymphoma (r/r DLBCL). Fact Sheet Nr. 181.
Rothschedl, E. and Grössmann, N. (2024): Durvalumab (Imfinzi®) in combination with carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent endometrial cancer (EC), followed by maintenance treatment durvalumab (Imfinzi®) as monotherapy in EC that is mismatch repair deficient (dMMR) or in combination with olaparib (Lynparza®) in EC that is mismatch repair proficient (pMMR). Fact Sheet Nr. 182.
Rothschedl, E. and Grössmann, N. (2024): Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL). Fact Sheet Nr. 183.
Rothschedl, E. and Grössmann, N. (2024): Sugemalimab (Cejemly®) with platinum-based chemotherapy for the first‑line treatment of metastatic non‑small‑cell lung cancer (NSCLC). Fact Sheet Nr. 177.
Rothschedl, E. and Grössmann, N. (2024): Osimertinib (Tagrisso®) with pemetrexed and platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 178.
Rothschedl, E. and Grössmann, N. (2024): Tislelizumab (Tevimbra®) monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Fact Sheet Nr. 179.
Rothschedl, E. and Grössmann, N. (2024): Fruquintinib (Fruzaqla®) as monotherapy for the treatment of metastatic colorectal cancer (mCRC). Fact Sheet Nr. 171.
Rothschedl, E. and Grössmann, N. (2024): Capivasertib (Truqap®) with fulvestrant for the treatment ER-positive, HER2‑negative locally advanced or metastatic breast cancer. Fact Sheet Nr. 172.
Rothschedl, E. and Grössmann, N. (2024): Alectinib (Alecensa®) as adjuvant treatment following complete tumour resection for adult patients with ALK‑positive non‑small cell lung cancer (NSCLC). Fact Sheet Nr. 173.
Rothschedl, E. and Grössmann, N. (2024): Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. Fact Sheet Nr. 174.
Rothschedl, E. and Grössmann, N. (2024): Entrectinib (Rozlytrek®) as monotherapy for the treatment of solid tumours with a NTRK gene fusion. Fact Sheet Nr. 175.
Rothschedl, E. and Grössmann, N. (2024): Amivantamab (Rybrevant®) with carboplatin and pemetrexed for the first‑line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations. Fact Sheet Nr. 176.
Rothschedl, E. and Grössmann, N. (2024): Tislelizumab (Tizveni®) in monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Fact Sheet Nr. 164.
Rothschedl, E. and Grössmann, N. (2024): Retifanlimab (Zynyz®) as monotherapy for the first line treatment of patients with metastatic or recurrent locally advanced Merkel cell carcinoma. Fact Sheet Nr. 165.
Rothschedl, E. and Grössmann, N. (2024): Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM). Fact Sheet Nr. 166.
Rothschedl, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) as pre- and post-operative treatment of resectable non small cell lung carcinoma (NSCLC). Fact Sheet Nr. 167.
Rothschedl, E. and Grössmann, N. (2024): Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Fact Sheet Nr. 168.
Rothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours. Fact Sheet Nr. 169.
Rothschedl, E. and Grössmann, N. (2024): Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC). Fact Sheet Nr. 170.
Rothschedl, E. and Grössmann, N. (2024): Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies. Update September 2024. Fact Sheet Nr. 162.
Rothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer. Update September 2024. Fact Sheet Nr. 163.
Rothschedl, E. and Grössmann, N. (2023): Avapritinib (Ayvakyt®) for the treatment of indolent systemic mastocytosis (ISM). Fact Sheet Nr. 157.
Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC). Fact Sheet Nr. 158.
Rothschedl, E. and Grössmann, N. (2023): Adagrasib (Krazati®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 159.
Rothschedl, E. and Grössmann, N. (2023): Momelotinib (Omjjara®) for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (PMF), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Fact Sheet Nr. 160.
Rothschedl, E. and Grössmann, N. (2023): Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update September 2024. Fact Sheet Nr. 161.
Rothschedl, E. and Grössmann, N. (2023): Zanubrutinib (Brukinsa®) with obinutuzumab for the treatment of refractory or relapsed follicular lymphoma (FL). Fact Sheet Nr. 151.
Rothschedl, E. and Grössmann, N. (2023): Elranatamab (Elrexfio®) as monotherapy for the treatment of relapsed and refractory multiple myeloma (MM). Fact Sheet Nr. 152.
Rothschedl, E. and Grössmann, N. (2023): Durvalumab (Imfinzi®) as monotherapy for the first line treatment of advanced or unresectable hepatocellular carcinoma (HCC). Fact Sheet Nr. 153.
Rothschedl, E. and Grössmann, N. (2023): Dostarlimab (Jemperli®) with carboplatin and paclitaxel for the treatment of mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) primary advanced or recurrent endometrial cancer (EC). Fact Sheet Nr. 154.
Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. Fact Sheet Nr. 155.
Rothschedl, E. and Grössmann, N. (2023): Rucaparib (Rubraca®) as monotherapy for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. Fact Sheet Nr. 156.
Rothschedl, E. and Grössmann, N. (2023): Brentuximab vedotin (Adcetris®) in combination with doxorubicin, vinblastine and dacarbazine for previously untreated CD30+ Stage III or IV Hodgkin lymphoma. Update February 2024. Fact Sheet Nr. 146.
Rothschedl, E. and Grössmann, N. (2023): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation. Update April 2024. Fact Sheet Nr. 147.
Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of non-small cell lung carcinoma (NSCLC). Update April 2024. Fact Sheet Nr. 148.
Rothschedl, E. and Grössmann, N. (2023): Melphalan flufenamide (Pepaxti®) in combination with dexamethasone for the treatment of multiple myeloma (MM). Fact Sheet Nr. 149.
Rothschedl, E. and Grössmann, N. (2023): Quizartinib (Vanflyta®) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by single-agent maintenance therapy for patients with newly diagnosed acute myeloid leukaemia (AML). Update February 2024. Fact Sheet Nr. 150.
Rothschedl, E. and Grössmann, N. (2023): Crisantaspase (Enrylaze®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). Update June 2024. Fact Sheet Nr. 138.
Rothschedl, E. and Grössmann, N. (2023): Cedazuridine/decitabine (Inaqovi®) for the treatment of newly diagnosed acute myeloid leukaemia (AML). Update December 2023. Fact Sheet Nr. 139.
Rothschedl, E. and Grössmann, N. (2023): Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer. Update December 2023. Fact Sheet Nr. 140.
Rothschedl, E. and Grössmann, N. (2023): Talquetamab (Talvey®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM). Update December 2023. Fact Sheet Nr. 141.
Rothschedl, E. and Grössmann, N. (2023): Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC). Update February 2024. Fact Sheet Nr. 143.
Rothschedl, E. and Grössmann, N. (2023): Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease. Update July/August 2023. Fact Sheet Nr. 144.
Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Update July/August 2023. Fact Sheet Nr. 145.
Rothschedl, E. and Grössmann, N. (2023): Tremelimumab (Imjudo®) with durvalumab (Imfinzi®) and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). Update October 2023. Fact Sheet Nr. 135.
Rothschedl, E. and Grössmann, N. (2023): Trifluridine/tipiracil (Lonsurf®, TAS-02) with bevacizumab for the treatment of metastatic colorectal cancer (CRC). Update October 2023. Fact Sheet Nr. 136.
Rothschedl, E. and Grössmann, N. (2023): Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer. Update October 2023. Fact Sheet Nr. 137.
Rothschedl, E. and Grössmann, N. (2023): Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Update July 2024. Fact Sheet Nr. 142.
Rothschedl, E. and Grössmann, N. (2023): Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL). Update February 2024. Fact Sheet Nr. 130.
Rothschedl, E. and Grössmann, N. (2023): Pirtobrutinib (JaypircaTM) as monotherapy for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL). Update December 2023. Fact Sheet Nr. 131.
Rothschedl, E. and Grössmann, N. (2023): Ivosidenib (Tibsovo®) monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma. Update February 2024. Fact Sheet Nr. 127.
Rothschedl, E. and Grössmann, N. (2020): Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM). Update February 2024. Oncology Fact Sheet Nr. 17.
Rothschedl, E. and Grössmann, N. : Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of advanced NSCLC. Fact Sheet Nr. 190.
Rothschedl, E. and Wolf, S. (2023): Nivolumab (Opdivo®) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC). Update October 2023. Fact Sheet Nr. 133.
Rothschedl, E. and Wolf, S. (2023): Piflufolastat (18F) (Pylclari®) for the diagnosis of prostate cancer. Update October 2023. Fact Sheet Nr. 134.
Rothschedl, E. and Wolf, S. (2023): Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma. Update July 2023. Fact Sheet Nr. 132.
Rothschedl, E. and Wolf, S. (2023): Niraparib/abiraterone acetate (Akeega®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update July 2023. Fact Sheet Nr. 125.
Rothschedl, E. and Wolf, S. (2023): Ivosidenib (Tibsovo®, Tidhesco® ) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML). Update June 2023. Fact Sheet Nr. 126.
Rothschedl, E. and Wolf, S. (2023): Cemiplimab (Libtayo®) in combination with platinum‐based chemotherapy for the first‐line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Update June 2023. Fact Sheet Nr. 128.
Rothschedl, E. and Wolf, S. (2023): Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). Update July 2023. Fact Sheet Nr. 129.
Rothschedl, E. and Wolf, S. (2023): Nadofaragene firadenovec (Adstiladrin®) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours. Update June 2023. Fact Sheet Nr. 121.
Rothschedl, E. and Wolf, S. (2023): Oportuzumab monatox for the treatment of noninvasive urothelial carcinoma in situ (CIS) previously treated with Bacillus Calmette-Guérin (BCG). Update June 2023. Fact Sheet Nr. 122.
Rothschedl, E. and Wolf, S. (2023): Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone‑sensitive prostate cancer (mHSPC). Update June 2023. Fact Sheet Nr. 123.
Rothschedl, E. and Wolf, S. (2023): Olaparib (Lynparza®) in combination with abiraterone and prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update April 2023. Oncology Fact Sheet Nr. 117.
Rothschedl, E. and Wolf, S. (2023): Tremelimumab (Imjudo®) in combination with durvalumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Update July 2023. Oncology Fact Sheet Nr. 118.
Rothschedl, E. and Wolf, S. (2023): Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). Update April 2023. Oncology Fact Sheet Nr. 119.
Rothschedl, E. and Wolf, S. (2023): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer. Update April 2023. Oncology Fact Sheet Nr. 120.
Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. Update April 2023. Oncology Fact Sheet Nr. 115.
Rothschedl, E. and Wolf, S. (2022): Durvalumab (Imfinzi®) in combination with gemcitabine and cisplatin for the first‑line treatment of unresectable or metastatic biliary tract cancer (BTC). Update April 2023. Oncology Fact Sheet Nr. 116.
Rothschedl, E. and Wolf, S. (2022): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL). Update March 2023. Fact Sheet Nr. 112.
Rothschedl, E. and Wolf, S. (2022): Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer. Update March 2023. Fact Sheet Nr. 113.
Rothschedl, E. and Wolf, S. (2022): Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update April 2023. Oncology Fact Sheet Nr. 114.
Rothschedl, E. and Wolf, S. (2022): Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Update July 2023. Fact Sheet Nr. 109.
Rothschedl, E. and Wolf, S. (2022): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of marginal zone lymphoma (MZL). Update March 2023. Fact Sheet Nr. 110.
Rothschedl, E. and Wolf, S. (2022): Axicabtagene ciloleucel (Yescarta®) for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Update March 2023. Fact Sheet Nr. 111.
Rothschedl, E. and Wolf, S. (2022): Relatlimab/nivolumab (Opdualag®) for the first line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%. Update December 2022. Oncology Fact Sheet Nr. 105.
Rothschedl, E. and Wolf, S. (2022): Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Update December 2022. Oncology Fact Sheet Nr. 106.
Rothschedl, E. and Wolf, S. (2022): Teclistamab (Tecvayli®) as monotherapy for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies. Update December 2022. Oncology Fact Sheet Nr. 107.
Rothschedl, E. and Wolf, S. (2022): Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC). Update March 2023. Fact Sheet Nr. 108.
Rothschedl, E. and Wolf, S. (2022): Melphalan flufenamide (Pepaxti®) with dexamethasone for the treatment of multiple myeloma (MM). Update October 2022. Oncology Fact Sheet Nr. 100.
Rothschedl, E. and Wolf, S. (2022): Asciminib (Scemblix®) for the treatment of Philadelphia chromosome‑positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP). Update November 2022. Oncology Fact Sheet Nr. 101.
Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer. Update November 2022. Oncology Fact Sheet Nr. 102.
Rothschedl, E. and Wolf, S. (2022): Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Update November 2022. Oncology Fact Sheet Nr. 103.
Rothschedl, E. and Wolf, S. (2022): Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer. Update December 2022. Oncology Fact Sheet Nr. 104.
Rothschedl, E. and Wolf, S. (2022): Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer. Oncology Fact Sheet Nr. 65.
Rothschedl, E. and Wolf, S. (2022): Degarelix (Firmagon®) for treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy. Oncology Fact Sheet Nr. 66.
Rothschedl, E. and Wolf, S. (2022): Selinexor (Nexpovio®) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma (MM). Update October 2022. Oncology Fact Sheet Nr. 98.
Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma who have undergone complete resection. Update October 2022. Oncology Fact Sheet Nr. 99.
Rothschedl, E. and Wolf, S. (2022): Mosunetuzumab (Lunsumio®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL) Update September 2022. Oncology Fact Sheet Nr. 92.
Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) in combination with chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of locally advanced, or early‑stage triple‑negative breast cancer (TNBC). Update September 2022. Oncology Fact Sheet Nr. 94.
Rothschedl, E. and Wolf, S. (2022): Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced RET fusion positive non-small cell lung cancer (NSCLC). Update December 2022. Oncology Fact Sheet Nr. 95.
Rothschedl, E. and Wolf, S. (2022): Atezolizumab (Tecentriq®) as adjuvant treatment following complete resection and platinum-based chemotherapy for patients with non-small cell lung cancer (NSCLC). Update September 2022. Oncology Fact Sheet Nr. 96.
Rothschedl, E. and Wolf, S. (2022): Axicabtagene ciloleucel (Yescarta®) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). Update September 2022. Oncology Fact Sheet Nr. 97.
Rothschedl, E. and Wolf, S. (2022): Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM). Update June 2022. Oncology Fact Sheet Nr. 86.
Rothschedl, E. and Wolf, S. (2022): Cabozantinib (Cabometyx®) as monotherapy for the treatment of locally advanced or metastatic differentiated thyroid carcinoma (DTC). Update June 2022. Oncology Fact Sheet Nr. 87.
Rothschedl, E. and Wolf, S. (2022): Tisagenlecleucel (Kymriah®) for the treatment of relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Update July 2022. Oncology Fact Sheet Nr. 88.
Rothschedl, E. and Wolf, S. (2022): Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL). Update July 2022. Oncology Fact Sheet Nr. 89.
Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the treatment of microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic colorectal cancer, advanced or recurrent endometrial carcinoma and unresectable or metastatic gastric, small intestine, or biliary cancer. Update July 2022. Oncology Fact Sheet Nr. 90.
Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for the treatment of persistent, recurrent, or metastatic cervical cancer. Update July 2022. Oncology Fact Sheet Nr. 91.
Rothschedl, E. and Wolf, S. (2022): Relugolix (Orgovyx®) for the treatment of advanced hormone-sensitive prostate cancer. Update November 2022. Oncology Fact Sheet Nr. 80.
Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC). Update June 2022. Oncology Fact Sheet Nr. 81.
Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) in combination with chemotherapy for the first-line treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Update June 2022. Oncology Fact Sheet Nr. 83.
Rothschedl, E. and Wolf, S. (2022): Abemaciclib (Verzenios®) in combination with endocrine therapy for the adjuvant treatment of early breast cancer. Update June 2022. Oncology Fact Sheet Nr. 84.
Rothschedl, E. and Wolf, S. (2022): Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer. Update June 2022. Oncology Fact Sheet Nr. 85.
Rothschedl, E. and Wolf, S. (2022): Tebentafusp (Kimmtrak®) as monotherapy for the treatment of human leukocyte antigen (HLA) A*02:01 positive patients with unresectable or metastatic uveal melanoma. Update March 2023. Fact Sheet Nr. 79.
Rothschedl, E. and Wolf, S. (2022): Lisocabtagene maraleucel (Breyanzi®) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). Update May 2022. Oncology Fact Sheet Nr. 77.
Rothschedl, E. and Wolf, S. (2022): Avapritinib (Ayvakyt®) for the treatment of advanced systemic mastocytosis (AdvSM). Update September 2022. Oncology Fact Sheet Nr. 78.
Rothschedl, E. and Wolf, S. (2022): Tepotinib (Tepmetko®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC). Update May 2022. Oncology Fact Sheet Nr. 73.
Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Update June 2022. Oncology Fact Sheet Nr. 82.
Rothschedl, E. and Wolf, S. (2022): Capmatinib (Tabrecta®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Update October 2022. Oncology Fact Sheet Nr. 93.
Rothschedl, E. and Wolf, S. (2021): Sotorasib (Lumykras®): Sotorasib (Lumykras®) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation. Update May 2022. Oncology Fact Sheet Nr. 71.
Rothschedl, E. and Wolf, S. (2021): Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST). Update May 2022. Oncology Fact Sheet Nr. 62.
Rothschedl, E. and Wolf, S. (2021): Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM). Update November 2022. Oncology Fact Sheet Nr. 39.
Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL). Withdrawal of the marketing authorisation in the European Union. Update November 2022. Oncology Fact Sheet Nr. 35.
Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Update September 2022. Oncology Fact Sheet Nr. 16.
Scott, A. and Hofer, V. and Al Froukh, R.F. and Ma, N. (2023): Electrical auricular vagus nerve stimulation for pain. Decision Support Document 138.
Scott, A. and Kern, J. and Vreugdenburg, T. (2024): Caval valve implantation (CAVI) for severe tricuspid regurgitation. Decision Support Document 139.
Sehic, O. (2021): Sponsoring of patient initiatives in Austria. Update of the Systematic Analyses 2014 to 2018. AIHTA Policy Brief 007.
Sehic, O. and Wild, C. (2022): ATMPs and Gene Therapies in Development. Horizon Scanning – Update 2022. AIHTA Policy Brief 006b/ 1. Update.
Sehic, O. and Wild, C. (2022): CAR-T Cell-Therapies in Development, Update 2022. AIHTA Policy Brief 006a/ 1. Update.
Sehic, O. and Wild, C. (2021): Non-interventional studies (NIS) in Austria, 2nd update of systematic analyses 2016 & 2017. AIHTA Policy Brief 010.
Semlitsch, T. and Jeitler, K. and Zipp, C. and Krenn, C. and Horvath, K. and Zens, Y. and Hausner, E. and Sauerland, S. and Störchel, M. and Sturtz, S. and Varela Lema, L. and Paz Valiñas, L. and Puñal Riobóo, J. and Cantero Muñoz, P. and Faraldo Vallés, M.J. (2020): Lung cancer screening in risk groups. HTA-Projektbericht 132a.
Semlitsch, T. and Krenn, C. (2024): Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB) in patients with coronary artery disease (CAD). 3rd Update. Decision Support Document 24/ 3. Update 2024.
Semlitsch, T. and Loder, C. (2023): Percutaneous mitral valve repair with a clip device in patients with mitral regurgitation. 2nd Update 2023. Decision Support Document 41/ Update 2023.
Semlitsch, T. and Zipp, C. and Loder, C. (2022): Percutaneous coronary interventions (PCI) for chronic total occlusion (CTO). Update 2022. Decision Support Document 64/ Update 2022.
Strohmaier, C. and Erdos, J. (2022): Lower Esophageal Sphincter Devices for Laparoscopic Surgery in Patients with Gastroesophageal Reflux Disease (GERD). Decision Support Document 134.
Strohmaier, C. and Gassner, L. (2022): Quality Registries in Dementia Care: Mapping of Registries to improve Quality and Service Delivery. HTA-Projektbericht 150.
Strohmaier, C. and Hölzle, L. (2021): The economic and societal dimension of parental mental illness. HTA-Projektbericht 142.
Strohmaier, C. and Kern, J. (2023): Registries in Austria and their utilisation for healthcare improvement. HTA-Projektbericht 157.
Strohmaier, C. and Zechmeister-Koss, I. (2024): Threshold values in health economic evaluations and decision-making. HTA-Projektbericht 163.
Walter, M. and Gassner, L. (2021): Liposuction for surgical therapy of lipoedema. Decision Support Document 125.
Walter, M. and Strohmaier, C. (2020): Genetic Testing in the Context of Familial Hypercholesterolaemia Management. HTA-Projektbericht 130.
Wild, C. (2020): Update 12 months follow-up: Nusinersen in spinal muscular atrophy ("late onset") in children and adolescents ≥ 6 years. AIHTA Policy Brief 001.
Wild, C. and Erdos, J. and Jeindl, R. (2024): Biomarkers in Parkinson's Disease. Rapid Review Nr.: 010.
Wild, C. and Fabian, D. (2024): The Role of Public Contributions to the Development of Health Innovations. HTA-Projektbericht 158.
Wild, C. and Sehic, O. (2020): Proton and carbon ion therapy - an update on indications. AIHTA Policy Brief 004.
Wild, C. and Wohlhöfner, K. and Sehic, O. and Grössmann, N. (2020): CAR-T Cell Therapies, ATMP and Gene Therapies in Development, Horizon Scanning: ATMPs and Gene Therapies. AIHTA Policy Brief 006b.
Wohlhöfner, K. (2021): (Good) practice organisational models using real-world evidence for public funding of high prized therapies. HTA-Projektbericht 138.
Wolf, S. (2022): Long COVID care pathways and structures: an updated scoping review. HTA-Projektbericht 135b/ Update.
Wolf, S. (2022): Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer. Oncology Fact Sheet Nr. 72.
Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC). Update March 2022. Oncology Fact Sheet Nr. 74.
Wolf, S. (2022): Lorlatinib (Lorviqua®) as monotherapy for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC). Update March 2022. Oncology Fact Sheet Nr. 75.
Wolf, S. (2022): Tegafur/gimeracil/oteracil (Teysuno®) for the treatment of metastatic colorectal cancer. Update March 2022. Oncology Fact Sheet Nr. 76.
Wolf, S. (2021): Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC). Update January 2022. Oncology Fact Sheet Nr. 67.
Wolf, S. (2021): Pembrolizumab (Keytruda) in combination with Lenvatinib (Lenvima®) for the treatment of advanced or recurrent endometrial carcinoma (EC). Update February 2022. Oncology Fact Sheet Nr. 68.
Wolf, S. (2021): Amivantamab (Rybrevant®) as monotherapy for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations. Update March 2022. Oncology Fact Sheet Nr. 69.
Wolf, S. (2021): Sacituzumab govitecan (Trodelvy) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC). Update January 2022. Oncology Fact Sheet Nr. 70.
Wolf, S. (2021): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with Waldenström's Macroglobulinaemia (WM). Update February 2022. Oncology Fact Sheet Nr. 60.
Wolf, S. (2021): Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC). Update March 2022. Oncology Fact Sheet Nr. 61.
Wolf, S. (2021): Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma. Update February 2022. Oncology Fact Sheet Nr. 63.
Wolf, S. (2021): Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC). Update February 2022. Oncology Fact Sheet Nr. 64.
Wolf, S. (2021): Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL). Update July 2021. Oncology Fact Sheet Nr. 38.
Wolf, S. (2021): Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC). Update March 2022. Oncology Fact Sheet Nr. 41.
Wolf, S. (2021): Idecabtagene vicleucel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM). Update September 2021. Oncology Fact Sheet Nr. 57.
Wolf, S. (2021): Tafasitamab (Minjuvi®; Monjuvi®) for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). Update November 2021. Oncology Fact Sheet Nr. 58.
Wolf, S. (2021): Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC). Update November 2021. Oncology Fact Sheet Nr. 59.
Wolf, S. (2021): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer. Update September 2021. Oncology Fact Sheet Nr. 51.
Wolf, S. (2021): Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC). Update September 2021. Oncology Fact Sheet Nr. 52.
Wolf, S. (2021): Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC). Update September 2021. Oncology Fact Sheet Nr. 53.
Wolf, S. (2021): Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapy for the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus. Update August 2021. Oncology Fact Sheet Nr. 54.
Wolf, S. (2021): Daratumumab (Darzalex®) in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (MM). Update September 2021. Oncology Fact Sheet Nr. 55.
Wolf, S. (2021): Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of newly diagnosed systemic light chain (AL) amyloidosis. Update September 2021. Oncology Fact Sheet Nr. 56.
Wolf, S. (2021): Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML). Update August 2021. Oncology Fact Sheet Nr. 47.
Wolf, S. (2021): Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC). Update August 2021. Oncology Fact Sheet Nr. 48.
Wolf, S. (2021): Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML). Update August 2021. Oncology Fact Sheet Nr. 49.
Wolf, S. (2021): Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma. Update August 2021. Oncology Fact Sheet Nr. 50.
Wolf, S. (2020): Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN). Update March 2022. Oncology Fact Sheet Nr. 28.
Wolf, S. and Al Froukh, R.F. (2023): 177Lu-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Systematic Review. 1st Update 2023. Decision Support Document 118/ Update 2023.
Wolf, S. and Erdos, J (2021): Epidemiology of long COVID: a preliminary report. German short version of the original KCE report. HTA-Projektbericht 135a.
Wolf, S. and Erdos, J. (2021): Long COVID care pathways: a systematic review. HTA-Projektbericht 135b.
Wolf, S. and Goetz, G. (2022): Subcutaneous implantable cardioverter-defibrillator (S-ICD). 1. Update 2022: Systematic review. Decision Support Document 109/ Update 2022.
Wolf, S. and Grössmann, N. (2020): Home-Treatment in Child and Adolescent Psychiatry: An Analysis of the Effectiveness and Possible Implementation in Austria. HTA-Projektbericht 129.
Wolf, S. and Kern, J. (2024): Strategies for reducing weight stigmatisation towards people with overweight or obesity in the healthcare system. HTA-Projektbericht 160.
Wolf, S. and Reinsperger, I. (2023): Strategies for recruitment and programme adherence in group programmes for children, adolescents and adults with overweight and grade 1 obesity. HTA-Projektbericht 155.
Wolf, S. and Strohmaier, C. (2021): Allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses. Decision Support Document 128.
Zechmeister-Koss, I. (2023): Perinatal and infant mental health care in Austria: A mapping of existing prevention, screening and care structures, with a specific focus on Tyrol. HTA-Projektbericht 151.
Zechmeister-Koss, I. and Kern, J. and Edlinger, M. (2024): Uptake of Mental Health Benefits in Women Before and During the Perinatal Period: An Analysis of Austrian Health Insurance Data. HTA-Projektbericht 154.